title: Fluticasone furoate nasal spray is effective and well tolerated for perennial allergic rhinitis in adolescents and adults.
abstract: BACKGROUND
  Fluticasone furoate nasal spray (FFNS), an intranasal corticosteroid, has been shown to be effective in perennial allergic rhinitis in randomized, double-blind, placebo-controlled studies but has been less extensively studied in perennial allergic rhinitis than seasonal allergic rhinitis. This study was designed to evaluate the efficacy and safety of FFNS in perennial allergic rhinitis in adolescents and adults ≥12 years of age.
  
  
  METHODS
  In this randomized, double-blind, placebo-controlled, parallel-group study (FFU111439), patients ≥12 years old with perennial allergic rhinitis received FFNS, 110 micrograms (n = 160), or placebo (n = 155) q.d. for 4 weeks.
  
  
  RESULTS
  Over the entire treatment period, FFNS was significantly (p < 0.05) more effective than placebo with respect to mean changes from baseline in daily reflective total nasal symptoms (primary end point), morning and evening reflective total nasal symptoms, daily reflective individual nasal symptoms, morning predose instantaneous total and individual nasal symptoms, and morning and evening peak nasal inspiratory flow. FFNS did not show a statistically significant difference from placebo in comparisons of ocular symptom measures. Clinically meaningful improvement versus placebo was observed on the Rhinoconjunctivitis Quality of Life Questionnaire with Standardised Activities overall score. Adverse events reported in >3% of patients in a treatment group and reported more frequently with FFNS than placebo were epistaxis (15% FFNS, 8% placebo) and nasopharyngitis (5% FFNS, 1% placebo).
  
  
  CONCLUSIONS
  Once-daily FFNS was well tolerated and more effective than placebo at improving nasal symptoms of perennial allergic rhinitis in adolescents and adults ≥12 years of age.
authors.affiliation: Allergy & Respiratory Center, 4048 Dressler Road NW, Canton, OH 44718, USA. debbieg@givenmd.com
authors.forename: John T
authors.initials: JT
authors.lastname: Given
authors.forename: Amarjit S
authors.initials: AS
authors.lastname: Cheema
authors.forename: Tilman
authors.initials: T
authors.lastname: Dreykluft
authors.forename: Allan
authors.initials: A
authors.lastname: Stillerman
authors.forename: MaryJane
authors.initials: M
authors.lastname: Silvey
authors.forename: Wei
authors.initials: W
authors.lastname: Wu
authors.forename: Neil G
authors.initials: NG
authors.lastname: Snowise
authors.forename: Edward
authors.initials: E
authors.lastname: Philpot
mesh_terms: D000293:Adolescent; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D059085:Nasal Sprays; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000523:psychology
chemical_list: D000730:Androstadienes; D059085:Nasal Sprays; C523187:fluticasone furoate